24th week of 2021 patent applcation highlights part 10 |
Patent application number | Title | Published |
20210177817 | METHODS FOR SHRINKING PITUITARY TUMORS - Pituitary tumors may be reduced in size by administration of relacorilant. Pituitary tumors include, without limitation, non-secreting tumors, hormone-secreting tumors, adenomas, and carcinomas. Relacorilant administration may be effective to reduce hormone secretion from a hormone-secreting pituitary tumor, e.g., to reduce adrenocorticotrophic hormone (ACTH) secretion. A pituitary tumor may be imaged before and/or after relacorilant administration. Relacorilant may be administered independent of surgery, and before, during, or after surgery to treat a pituitary tumor. Relacorilant may aid or improve surgical outcomes, and may reduce the size or growth of pituitary tumor tissue before surgery, and any tumor tissue remaining following surgical treatment. | 2021-06-17 |
20210177819 | METHODS AND COMPOSITIONS FOR MODULATING CALCIUM CHANNELS - The present invention relates to methods and compositions for modulating calcium channels. In particular, the present invention provides methods and compositions for modulating (e.g., disrupting) Cav1.3a calcium channels for research and therapeutic methods (e.g., treating dopaminergic diseases and conditions). | 2021-06-17 |
20210177820 | USES OF A LYSYL OXIDASE-LIKE 2 INHIBITOR - Described herein is the use of a LOXL2 inhibitor in the treatment or prevention of conditions, diseases, or disorders associated with LOXL2 activity. | 2021-06-17 |
20210177821 | Androgen Receptor Modulator And Uses Thereof - Described herein is the androgen receptor modulator of formula (I) | 2021-06-17 |
20210177822 | PHARMACEUTICAL COMPOSITION COMPRISING PIMAVANSERIN, PROCESS OF PREPARATION AND USE THEREOF - The present invention relates to prepare pharmaceutical compositions comprising pimavanserin or a pharmaceutically acceptable salt thereof, processes for manufacturing said pharmaceutical compositions comprising pimavanserin or a pharmaceutically acceptable salt thereof. Also pharmaceutical compositions comprising pimavanserin or a pharmaceutically acceptable salt thereof for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. | 2021-06-17 |
20210177823 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER - Described herein are methods for treating a subject having or at risk of developing cancer by administering a neuromodulating agent. | 2021-06-17 |
20210177824 | EXTENDED RELEASE FORMULATIONS FOR INTRA-ARTICULAR APPLICATIONS - The present invention relates to a pharmaceutical composition comprising an aqueous suspension of: (i) crystalline N-(3,4-dichlorophenyl)-3-(pyridin-4-yl)-7-oxabicyclo[2.2.1]heptane-2-carboxamide or a pharmaceutically acceptable salt thereof; and (ii) a surfactant comprising a water-soluble co-polymer characterized by >5% solubility in water at 25° C. The compositions provide extended release of N-(3,4-dichlorophenyl)-3-(pyridin-4-yl)-7-oxabicyclo[2.2.1] heptane-2-carboxamide, and are suitable for intra-articular injection to a joint of a patient suffering from arthritis, joint injury or cartilage injury. | 2021-06-17 |
20210177825 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION - Disclosed are small molecules against cereblon to enhance effector T cell function. Methods of making these molecules and methods of using them to treat various disease states are also disclosed. | 2021-06-17 |
20210177826 | ANTI-TUMOR EFFECT POTENTIATOR USING NOVEL BIPHENYL COMPOUND - An antitumor formulation comprising a biphenyl compound having LSD1 inhibitory activity or a salt thereof and one or more other antitumor agents that are administered in combination, the compound being represented by Formula (I): | 2021-06-17 |
20210177827 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF - The disclosure relates to compounds that are, e.g., PAP Associated Domain Containing 5 (PAPD5) inhibitors and methods of use thereof. | 2021-06-17 |
20210177828 | TAM FAMILY KINASE /AND CSF1R KINASE INHIBITOR AND USE THEREOF - The present invention provides a novel inhibitor compound of general formula (I), exhibiting excellent kinase inhibitor activity. The compound of the present invention can be used to prevent and/or treat diseases mediated by abnormal expression of TAM family kinase receptors and/or ligands thereof. In addition, the compound of the present invention can also target CSF1R kinase, and thus can be used to prevent and/or treat diseases mediated by abnormal expression of TAM family kinase receptors and/or CSF1R kinase receptors and/or ligands thereof. | 2021-06-17 |
20210177829 | SOLID FORMS OF ((S)-5-((1-(6-CHLORO-2-OXO-1,2-DIHYDROQUINOLIN-3-YL)ETHYL)AMINO)-1-METHYL- -6-OXO-1,6-DIHYDROPYRIDINE-2-CARBONITRILE - The present disclosure reports solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile. | 2021-06-17 |
20210177830 | COMPOSITIONS FOR TREATING OR PREVENTING VASOMOTOR SYMPTOMS - The present disclosure is directed to compositions and methods for treating or preventing vasomotor symptoms such as hot flashes, comprising a Transient Receptor Potential Melastatin 8 (TRPM8) antagonist and administering a TRPM8 antagonist, respectively. | 2021-06-17 |
20210177831 | COMPOSITIONS AND METHODS FOR LOCAL DELIVERY OF PHARMACEUTICAL AGENTS TO TREAT CANCER - Described herein are compositions comprising a T cell/thymic stromal lymphopoietin (TSLP) activating agent and an innate immunity activating agent, an methods of use thereof to treat cancer, e.g., cutaneous malignancies. | 2021-06-17 |
20210177832 | INHIBITORS OF RNA-GUIDED NUCLEASE TARGET BINDING AND USES THEREOF - Compositions and methods for inhibiting the activity of RNA-guided endonucleases, and methods for identifying such compositions are included. Methods of treatment using the inhibitory compounds, formulations and methods are also detailed, as well as control of nucleic acid editing systems and methods using said compounds. | 2021-06-17 |
20210177834 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION - Described herein are dosage forms of enantiomerically enriched (S)-bupropion or enantiomerically enriched (R)-bupropion. The (S)-bupropion or the (R)-bupropion may be deuterium enriched, or may have natural isotopic abundance. These dosage forms may be administered, either fed or fasted, to treat a condition recited herein, to achieve a certain pharmacokinetic parameter of a bupropion or a metabolite of a bupropion, and/or to enhance dextromethorphan plasma levels. | 2021-06-17 |
20210177835 | LEVOCETIRIZINE AND MONTELUKAST IN THE TREATMENT OF INFLAMMATION MEDIATED CONDITIONS - The embodiments described herein include methods and formulations for treating viruses and diseases that are exacerbated by inflammatory responses in the body. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient. | 2021-06-17 |
20210177836 | PLATINUM COMPOUNDS THAT INHIBIT CONSTITUTIVE STAT3 SIGNALING AND INDUCE CELL CYCLE ARREST AND APOPTOSIS OF MALIGNANT CELLS - The subject invention concerns a compound and compositions having activity as an inhibitor of Stat3 protein and methods of using the compound and compositions. In one embodiment, a compound of the invention has the structure shown in formula I, formula II, or formula III. The subject invention also concerns methods of using the compounds and compositions of the invention. | 2021-06-17 |
20210177837 | CERTAIN ARYL PLADIENOLIDE COMPOUNDS AND METHODS OF USE - The present disclosure provides pladienolide compounds, pharmaceutical compositions containing such compounds, and pladienolide compounds for use in methods of medical treatment. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are pladienolide compounds for use in methods of treating cancers by administering at least one pladienolide compound disclosed herein and at least one additional therapy. | 2021-06-17 |
20210177838 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR - The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer. | 2021-06-17 |
20210177839 | IMPROVED BROMOCRIPTINE FORMULATIONS - The present disclosure describes pharmaceutical formulations of bromocriptine and methods of manufacturing and using such formulations. The formulations are useful for treating physiological disorders including improving glycemic control in the treatment of type 2 diabetes. Also disclosed is synthesis of bromocriptine citrate, and compositions and dosage forms containing bromocriptine citrate. | 2021-06-17 |
20210177840 | LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF) - This invention relates to the treatment of Pulmonary Hypertension with heart failure with preserved ejection fraction (PH-HFpEF). More specifically, embodiments of the invention provide compositions and methods useful for the treatment of PH-HFpEF employing the use of levosimendan. | 2021-06-17 |
20210177841 | CONJOINT THERAPY WITH GLUTAMINASE INHIBITORS - The invention relates to methods of treating cancer using novel heterocyclic glutaminase inhibitor compounds conjointly with a PD1 or PD-L1 inhibitor. | 2021-06-17 |
20210177842 | PIMOBENDAN FORMULATION AND METHOD OF USE THEREOF - Provided herein are chewable oral formulations including pimobendan for use in mammals to treat cardiac disorders. | 2021-06-17 |
20210177843 | Long Term Treatment of HIV-Infection With TMC278 - This invention relates to the use of a parenteral formulation comprising an anti-virally effective amount of TMC278 or a pharmaceutically acceptable acid-addition salt thereof, and a carrier, for the manufacture of a medicament for the treatment of a subject being infected with HIV, wherein the formulation is to be administered intermittently at a time interval of at least one week. | 2021-06-17 |
20210177844 | Combination of EGFR Inhibitor and MEK Inhibitor for use in the treatment of NRAS mutated cancer - The invention relates to the methods for identifying resistance to cancer therapy, by identification of an E63K NRAS mutation, a G12V NRAS mutation or a gain of copy number of NRAS gene. A further aspect of the invention relates to methods of treatment that may overcome such resistance mechanisms, involving the use of an EGFR inhibitor in combination with a MEK inhibitor for the treatment of cancers involving an NRAS mutation selected from E63K, G12V, G12R, G12A, G12D, G12S and G12C, and/or cancer involving a gain of copy number of NRAS gene. | 2021-06-17 |
20210177845 | PDE9 INHIBITORS FOR TREATING SICKLE CELL DISEASE - The present disclosure relates to PDE9 inhibitors, pharmaceutical compositions comprising the PDE9 inhibitors, and methods of using the PDE9 pharmaceutical compositions for the treatment of sickle cell disease (SCD). | 2021-06-17 |
20210177846 | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS - The present disclosure relates to methods, uses, pharmaceutical compositions comprising an sGC stimulator or a pharmaceutically acceptable salt thereof, alone or in combination with one or more additional therapeutic agents, for the treatment of a mitochondrial disorder. | 2021-06-17 |
20210177847 | Compounds for treatment of diseases related to DUX4 expression - The present invention relates to compounds for the treatment of diseases related to DUX4 expression, such as muscular dystrophies. It also relates to use of such compounds, or to methods of use of such compounds. | 2021-06-17 |
20210177848 | Methods of Treating Antipsychotic-Induced Weight Gain with Miricorilant - Methods of Treating Antipsychotic-Induced Weight Gain with Miricorilant Methods and compositions for treating a subject at risk of, or suffering from antipsychotic-induced weight gain are disclosed. The methods include administration of a cyclohexyl pyrimidine glucocorticoid receptor modulator (GRM) such as miricorilant (CORT118335) to a patient receiving, or who has received, or who is expected to receive, an antipsychotic drug such as olanzapine, risperidone, clozapine, or other weight-inducing antipsychotic medication. The GRM (e.g., miricorilant) may be orally administered. Administration of such a GRM along with antipsychotic medication may reduce the amount of weight, or reduce the rate of weight gain, or prevent weight gain, otherwise due to antipsychotic medication alone. The methods may reverse weight gain in a patient previously administered antipsychotic medication. Administration of such a GRM with antipsychotic medication may reduce, or reduce gain in, or prevent gain in, or reverse gain in, insulin resistance or blood levels of liver enzymes (AST, ALT), triglycerides, or insulin. | 2021-06-17 |
20210177849 | Therapeutic Compositions - The invention relates to a product containing the compound of formula (I) below (I) or a pharmaceutically acceptable salt of this compound, in combination with at least one compound having PDE5-inhibitory properties, or a pharmaceutically acceptable salt thereof, for therapeutic use, simultaneously, separately or over a period of time, in the treatment of a disease wherein vasoconstriction is involved. | 2021-06-17 |
20210177850 | METHOD FOR TREATING CANCER PATIENTS WITH SEVERE RENAL IMPAIRMENT - A method for treating cancer in patients with creatinine clearance of 15 mL/min or more and less than 30 mL/min, including dividing a combination drug containing α,α,α-trifluorothymidine (FTD) and 5-chloro-6-[(2-iminopyrrolidine-1-yl)methyl]pyrimidine-2,4(1H,3H)-dione hydrochloride in a molar ratio of 1:0.5, in a dose of 30 to 50 mg/m | 2021-06-17 |
20210177851 | NOVEL BENZYLAMINO SUBSTITUTED QUINAZOLINES AND DERIVATIVES AS SOS1 INHIBITORS - The present invention encompasses compounds of formula (I) | 2021-06-17 |
20210177852 | TTP PHOSPHORYLATION AS A BIOMARKER IN TARGETED THERAPY - The present invention relates to a method of determining if a patient is likely to respond to a treatment with a targeted therapy compound selected from protein kinase inhibitors, small molecule inhibitors, and monoclonal antibody-based compounds. The present invention further relates to a method of identifying a targeted therapy compound selected from protein kinase inhibitors, small molecule inhibitors, and monoclonal antibody-based compounds for personalized medicine. The present invention also relates to a method of treatment of cancer in a patient. The present invention also relates to a targeted therapy compound selected from protein kinase inhibitors, small molecule inhibitors, and monoclonal antibody-based compounds for use in a method of treatment of cancer in a patient. | 2021-06-17 |
20210177853 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS - The invention provides substituted pyrrolo[1,2-a]pyrimidines and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted pyrrolo[1,2-a]pyrimidines compounds described herein include substituted 2,4-dimethyl-N-phenylpyrrolo[1,2-a]pyrimidine-8-carboxamide compounds and variants thereof. | 2021-06-17 |
20210177854 | METHODS OF TREATING AND PREVENTING ALLOANTIBODY DRIVEN CHRONIC GRAFT VERSUS HOST DISEASE - Described herein are methods for treating and preventing alloantibody driven chronic graft versus host disease (cGVHD). The methods include administering to an individual in need thereof ibrutinib for treating and preventing alloantibody driven graft versus host disease. | 2021-06-17 |
20210177855 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS - The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy. | 2021-06-17 |
20210177856 | USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS - Disclosed are methods of treating a cancer in a subject using an ATR inhibitor and PARP inhibitor. wherein the cancer has been previously identified as a cancer having a loss of function of ATM, BRCA2, RNAse H2A, RNAse H2B, CDK12, or a combination thereof, or as an ALT+ cancer. Also disclosed are methods of inducing cell death in an aberrant cancer cell having a loss of function of ATM, BRCA2, RNAse H2A, RNAse H2B, CDK12, or a combination thereof, or an ALT+ cancer cell, by contacting the cell with an effective amount of an ATR inhibitor and PARP inhibitor. | 2021-06-17 |
20210177857 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING THE SAME - The present disclosure generally relates to nanoparticles comprising a substantially hydrophobic acid and a therapeutic agent (1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea), or pharmaceutically acceptable salts thereof, and a polymer. Other aspects include methods of making and using such nanoparticles. | 2021-06-17 |
20210177858 | COMPOSITIONS AND METHODS FOR CONTROLLING CERUMEN PRODUCTION - The present invention generally relates to compositions, formulations, methods, devices and kits for modulating the production of cerumen, for the treatment and prevention of excessive or impacted cerumen, and for the treatment and prevention of associated diseases, conditions or symptoms resulting from excessive or impacted cerumen. | 2021-06-17 |
20210177859 | COMBINATION THERAPY WITH NOTCH AND PI3K/MTOR INHIBITORS FOR USE IN TREATING CANCER - Medicaments for use in treating T-cell acute lymphoblastic leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, breast cancer, ovarian cancer, melanoma, lung cancer, pancreatic cancer, glioblastoma, sarcoma, desmoid tumors, adenoid cystic carcinoma, colorectal cancer, head and neck cancer, cervical cancer, prostate cancer, liver cancer, or skin cancer in a patient comprising combination therapy with 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxoethyl]butanamide, or a phamlaceutically acceptable salt or hydrate thereof, and 8-[5-(1-hydroxy-1-methylethyl)pyridin-3-yl]-1-[(2S)-2-methoxypropyl]-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one, or a pharmaceutically acceptable salt thereof. | 2021-06-17 |
20210177860 | COMPOSITIONS AND METHODS FOR DELIVERING PHARMACEUTICAL AGENTS - Provided herein are compositions and methods for treating pulmonary hypertension. In particular, provided herein are dry powder formulations of fasudil for delivery to the lung. | 2021-06-17 |
20210177861 | NRF2 ACTIVATOR FOR THE TREATMENT OF ACUTE LUNG INJURY, ACUTE RESPIRATORY DISTRESS SYNDROME AND MULTIPLE ORGAN DYSFUNCTION SYNDROME - The present invention relates to the use of an NRF2 activator to treat respiratory diseases. In particular, the present invention relates to the treatment of respiratory diseases, in a mammal, in which related organ failure accompanied by accumulation of alveolar fluid, hypoxemia, cough, wheezing, dyspnea, hyperpnea and pulmonary inflammation has occurred. | 2021-06-17 |
20210177862 | METHOD FOR TREATING NEUROCOGNITIVE DYSFUNCTION - A method of treating corticosteroid-induced cognitive impairment comprises administering an effective amount of at least one compound of formula I, or pharmaceutically acceptable salts thereof, to a subject in need of such treatment Formula I is: | 2021-06-17 |
20210177863 | LOW BENZALKONIUM CHLORIDE BIMATOPROST OPHTHALMIC COMPOSITIONS WITH EFFECTIVE PENETRATION & PRESERVATION PROPERTIES - The present invention relates to ophthalmic compositions comprising from 0.005% to 0.02% bimatoprost by weight, less than 100 ppm benzalkonium chloride, and a secondary penetration enhancer that detectably enhances penetration of bimatoprost into a mammalian eye such that elevated intraocular pressure is effectively reduced to an extent statistically comparable to compositions comprising higher amounts of bimatoprost and benzalkonium chloride. Further, the invention also provides a process of preparing such compositions and methods of their use for lowering intraocular pressure and treating glaucoma. | 2021-06-17 |
20210177864 | J-SERIES PROSTAGLANDIN-ETHANOLAMIDES AS NOVEL THERAPEUTICS FOR SKIN AND/OR ORAL DISORDERS - Provided is a method of preventing and/or treating a skin disorder and/or an oral disorder including administering to a subject in need thereof an effective amount of a compound of formula (I): | 2021-06-17 |
20210177865 | Steroidal Compositions - Provided herein are steroid containing compositions suitable for providing therapeutically effective amounts of at least one steroid to individuals. Also provided herein are compositions comprising testosterone and/or testosterone derivatives suitable for providing therapeutically effective and safe amounts of testosterone over periods of time. Further provided are methods of treating andro- and/or testosterone deficiency in individuals by administering to the individuals compositions described herein. | 2021-06-17 |
20210177866 | PROCESS FOR PREPARING A DRY POWDER FORMULATION COMPRISING AN ANTICHOLINERGIC, A CORTICOSTEROID AND A BETA-ADRENERGIC - Dry powder formulations for inhalation containing a combination of an anticholinergic, a long-acting beta | 2021-06-17 |
20210177867 | COMPOSITIONS OF BILE ACIDS AND PHENYLBUTYRATE COMPOUNDS - The present disclosure relates to compositions including a phenylbutyrate compound and a bile acid, and methods of processing such compositions. | 2021-06-17 |
20210177868 | NOVEL USE OF PHYTOSTENONE - According to the present invention, a transdermal absorbent for reducing a subcutaneous fat is provided, which comprises phytostenone. Accordingly, a method for further reducing a subcutaneous fat can be provided. | 2021-06-17 |
20210177870 | COMPOSITION CONTAINING PLASMALOGEN FOR ENHANCING MEMORIZATION ABILITY - This is to provide a useful application of plasmalogen, which is not yet known. | 2021-06-17 |
20210177871 | METHODS FOR CANCER THERAPY - The present disclosure relates to methods or dosing regimens comprising a proteasome inhibitor of formula (I), or a pharmaceutically acceptable salt thereof, | 2021-06-17 |
20210177872 | COMPOSITIONS FOR USE IN IMPROVING STOOL CONSISTENCY OR FREQUENCY IN INFANTS OR YOUNG CHILDREN - The present invention relates to a nutritional composition comprising at least one fucosylated oligosaccharide and at least one N-acetylated oligosaccharide, for use in preventing and/or treating constipation and/or in improving stool consistency/frequency in an infant or a young child. | 2021-06-17 |
20210177873 | Anticancer Composition of Traditional Chinese Medicine and Preparation Method Thereof - A medication of natural Chinese medicine with sustained release for cancer treatment and its preparation method thereof contains active ingredients of: ginsenoside, | 2021-06-17 |
20210177874 | COMPOSITION FOR PREVENTING OR ALLEVIATING NONALCOHOLIC FATTY LIVER DISEASE - The present invention relates to a composition for inhibiting liver fat accumulation comprising allulose as an active ingredient and a pharmaceutical composition and a food composition using thereof. | 2021-06-17 |
20210177875 | METHODS AND COMPOSITIONS FOR TREATING CHILDHOOD OR TEEN OBESITY - Provided herein are methods and compositions related to treating and/or preventing obesity and/or conditions associated with obesity in a subject by administering to the subject (e.g., orally administering to the subject) a composition comprising nicotinamide riboside and/or pterostilbene. | 2021-06-17 |
20210177876 | INOSITOL PHOSPHATE-CONTAINING COMPOSITION - The present invention further provides a composition for inhibiting purine body absorption, a composition for inhibiting purine nucleotide metabolism, a composition for inhibiting phosphatase, a composition for inhibiting uric acid level elevation, a composition for improving blood pressure, a composition for improving blood glucose level, a composition for improving liver function, a composition for controlling serum iron level, or a composition for promoting calcium absorption, comprising an inositol phosphate or a salt thereof. The present invention further provides a composition comprising an inositol phosphate or a salt thereof, wherein the taste thereof is improved by adding thereto a predetermined amount of calcium lactate. | 2021-06-17 |
20210177877 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE - Disclosed herein are active agents, compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or nonalcoholic fatty liver disease marker. | 2021-06-17 |
20210177878 | METHODS OF MOBILIZING MARROW INFILTRATING LYMPHOCYTES AND USES THEREOF - Methods are disclosed for the mobilization of marrow infiltrating cells (MILs) using E-selectin antagonists for the treatment of disorders such as cancer. Methods for treating or preventing cancers using MILs mobilized by E-selectin antagonists are further disclosed. | 2021-06-17 |
20210177879 | VITAMIN D RECEPTOR AGONIST - The present invention belongs to the technical field of biomedicine, and in particular relates to a vitamin D receptor agonist, where the agonist includes: one or more of monotropein, desacetyl asperulosidic acid, asperuloside, and asperulosidic acid; and studies have shown that one or more of monotropein, desacetyl asperulosidic acid, asperuloside, and asperulosidic acid can well activate vitamin D receptors, and thus have preventive and therapeutic effects on breast cancer, pancreatic cancer, and colon cancer by activating the vitamin D receptors. | 2021-06-17 |
20210177880 | METHODS AND COMPOSITIONS FOR TREATING ACUTE MYELOID LEUKEMIA - The disclosure relates to compositions, methods, and kits for treating leukemia, specifically acute myeloid leukemia, in a subject, and for detecting chemoresistant acute myeloid leukemic cells. | 2021-06-17 |
20210177881 | MEDICAMENT FOR PREVENTING AND/OR TREATING PAIN AND/OR FEVER, COMPOSITE PRODUCT AND USE THEREOF - The present disclosure discloses a medicament for preventing and/or treating pain and/or fever, a composite product and use thereof. An effective component of the medicament includes one of carrimycin, isovalerylspiramycin III, isovalerylspiramycin II and isovalerylspiramycin I; or a combination of two or three of isovalerylspiramycin I, isovalerylspiramycin II and isovalerylspiramycin III. | 2021-06-17 |
20210177882 | Treatment of Inflammatory Lesions of Rosacea with Ivermectin - Methods for safe and effective treatment of inflammatory lesions of rosacea in a subject are described. The methods involve once daily topically applying to an affected skin area a topical composition containing ivermectin and a pharmaceutically acceptable carrier. It has been demonstrated that once daily topical treatment with ivermectin is significantly superior than twice-daily topical treatment with metronidazole in reducing inflammatory lesion counts. | 2021-06-17 |
20210177883 | COMPOSITION FOR TREATING A PATIENT SUFFERING FROM ULCERATIVE COLITIS, AND USE OF THE COMPOSITION AS A DRUG - The invention relates to a composition for treating a patient suffering from an intestinal condition associated with chronic inflammation, wherein the composition comprises at least one DNAzyme which specifically inhibits the expression of GATA-3. A further aspect of the invention relates to the use of such a composition as drug. | 2021-06-17 |
20210177884 | COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF - The invention relates to iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the complement component C5 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of C5 and to treat subjects having a complement component C5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria. | 2021-06-17 |
20210177885 | REAGENTS FOR TREATMENT OF HEPATITIS B VIRUS (HBV) INFECTION AND USE THEREOF - This disclosure relates to RNA interference (RNAi) reagents for treatment of hepatitis B virus (HBV) infection, compositions comprising same, and use thereof to treat individuals infected with HBV. | 2021-06-17 |
20210177886 | PREBIOTIC FOR TREATING DISORDERS ASSOCIATED WITH DISTURBED COMPOSITION OR FUNCTIONALITY OF THE INTESTINAL MICROBIOME - The invention relates to a prebiotic composition for use in a method of therapeutic or prophylactic treatment of disorders associated with disturbed composition or functionality of the intestinal microbiome in a subject, said use comprising oral administration of the prebiotic composition to the subject, wherein the composition contains at least 0.1% by weight of dry matter of RG-I polysaccharides originating from fruit, carrot, pea, chicory or sugar beet, said RG-I polysaccharides having a molecular weight in excess of 15 kDa and having a backbone consisting of galacturonic acid residues and rhamnose residues, said rhamnose residues being contained in alpha(1→4)-galacturonic-alpha(1→2)-rhamnose residues, wherein the molar ratio of galacturonic acid residues to rhamnose residues in the RG-I polysaccharides is within the range of 20:1 to 1:1. | 2021-06-17 |
20210177887 | COMPOSITIONS AND METHODS FOR TREATING ELASTIC FIBER BREAKDOWN - The present disclosure relates to pharmaceutical compositions capable of regulating elastic fiber. The disclosure further relates to methods of treating elastic fiber-related disorders, such as COPD, by inhalation of low-molecular weight hyaluronic acid. | 2021-06-17 |
20210177888 | TOPICALLY ADMINISTERED STRONTIUM-CONTAINING COMPLEXES FOR TREATING PAIN, PRURITIS AND INFLAMMATION - Therapeutically-active compositions that combine strontium with at least one additional molecules that increase the overall therapeutic potency of the combination beyond the potency of any of the separate constituents. Specifically, the combinations perform two important functions; (1) they increase the ability of topically-applied strontium to inhibit both acute sensory irritation (e.g., pruritus and pain), redness, swelling and inflammation (collectively defined for purposes of this description, “irritation”) and the chronic irritation that is characteristic of and contributes to the development and maintenance of painful or pruritic neuropathic conditions; and (2) they decrease the strontium activated pathways that are known to enhance the development and maintenance of pain, pruritis and neuropathic conditions. | 2021-06-17 |
20210177889 | GASEOUS PHARMACEUTICAL COMPOSITION FOR HYPERTENSION THERAPY - The object of the invention is to provide a novel pharmaceutical composition for hypertension therapy that can be applied to a wide range of hypertensive patients. | 2021-06-17 |
20210177890 | COMPOSITION CONTAINING CHLORINE DIOXIDE AND METHODS FOR USING SAME - The present invention relates to a composition comprising chlorine dioxide useful in the treatment of active infections of the eye, as well as prophylaxis and treatment of such infections. The invention also relates to uses of compositions including effective amounts of chlorine dioxide in the eye to obtain benefit without detrimentally affecting the eye. | 2021-06-17 |
20210177891 | METHODS AND COMPOSITIONS FOR TREATING STROKE - Some embodiments include methods of treating, inhibiting, or ameliorating ischemic stroke or a symptom thereof in a subject. Some embodiments include oxygenated fluid for use in treating, inhibiting, or ameliorating ischemic stroke. The oxygenated fluid may comprise charge-stabilized oxygen-containing nanostructures. | 2021-06-17 |
20210177892 | PREVENTION AND TREATMENT OF INFECTIOUS DISEASE USING LOW CONCENTRATION HYPOCHLOROUS ACID SOLUTIONS - Systems and methods for prevention and treatment of infectious diseases using low concentration hypochlorous acid solutions are disclosed. In one embodiment, a method may include delivering an antiseptic solution to the medical equipment to disinfect the medical equipment used by the patient, thereby preventing infection by the infectious diseases in the patient. The antiseptic solution may include an aqueous solution of hypochlorous acid. The hypochlorous acid may be between 30 parts per million (ppm) to 500 ppm of the aqueous solution. | 2021-06-17 |
20210177893 | Composition and method for treating and healing Medication-Related Osteonecrosis of the Jaw (MRONJ) - A composition and method of preventing and treating all forms of osteonecrosis of the jaw are disclosed. The composition is comprised of 0.005 %-1.5% weight/volume (w/v) stannous salt, such as stannous fluoride, stannous chloride, or similar and may take the form of gel or similar. The prevention and treatment includes the application of the composition in the oral cavity and other body areas affected by Medication-Related Osteonecrosis of the Jaw (MRONJ). | 2021-06-17 |
20210177894 | Bis-Choline Tetrathiomolybdate for Treating Wilson Disease - Methods for treating Wilson Disease with bis-choline tetrathiomolybdate therapy are provided. The methods may include administering 15 mg or between 30 and 90 mg of bis-choline tetrathiomolybdate once daily to a patient exhibiting NCC | 2021-06-17 |
20210177895 | METHODS OF MODULATING M2 MACROPHAGE POLARIZATION AND USE OF SAME IN THERAPY - A method of treating a disease or disorder that can benefit from increasing an M2/M1 macrophage ratio in a subject in need thereof is provided. The method comprising: (a) culturing basophils in the presence of IL33 and/or GM-SCF; and (b) administering to the subject a therapeutically effective amount of the basophils following the culturing, thereby treating the disease or disorder that can benefit from increasing an M2/M1 macrophage ratio in the subject. | 2021-06-17 |
20210177896 | THERAPEUTIC REGIMENS FOR CHIMERIC ANTIGEN RECEPTOR (CAR)- EXPRESSING CELLS - The invention provides a method of treating an adult subject having a hematological cancer, comprising administering to the subject selected dosage regimens comprising a plurality of immune effector cells expressing a CAR molecule. | 2021-06-17 |
20210177897 | ARGINASE SUPPRESSION FOR CANCER TREATMENT - The present invention concerns a method for treating cancer, including haematological and solid tumors. In an embodiment, the method comprises impairing arginase activity and/or expression in immune cells, in particular T cells of a patient suffering from cancer. Arginase expression may be impaired by mutation (including deletion or truncation) of the arginase encoding gene, by RNA interference or by administration of an arginase inhibitor. In a preferred embodiment, the T cells are modified in the frame of CAR (Chimeric Antigen Receptor) therapy. The invention also provides a method of treatment combining impaired arginase activity with antibody-mediated blockage of negative immune checkpoint regulators (PDLL-PD1 and B7-CTLA4 inhibitory pathways). | 2021-06-17 |
20210177898 | METHODS AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY - The present disclosure relates to genetically modified T cells comprising a transgene encoding an engineered antigen specific receptor, wherein expression of an endogenous gene selected from MNK1, MNK2, or both are inhibited in the genetically modified T cell in order to enhance central memory T cell subsets in cellular immunotherapy compositions. | 2021-06-17 |
20210177899 | GENOME EDITING OF GRAFT-DERIVED T-CELLS FOR POST-TRANSPLANT IMMUNOTHERAPY - Methods and compositions for modifying allogeneic donor αβ T cells for use in the treatment of high risk leukemias are provided. | 2021-06-17 |
20210177900 | CD19 AND CD22 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF - The present disclosure provides compositions and methods for treating diseases associated with expression of CD19 and/or CD22, e.g., by administering a recombinant T cell or natural killer (NK) cell comprising a CD22 CAR and a CD19 CAR as described herein. The disclosure also relates to CAR molecules specific to CD22 and/or CD19, methods of making a cell comprising the same and vectors encoding the same. | 2021-06-17 |
20210177901 | Novel method for identifying deltaT-cell (or gammaT-cell) receptor chains or parts thereof that mediate an anti-tumour or an anti-infective response - The present invention relates to a method for identifying δT-cell (or γT-cell) receptors chains or parts thereof that mediate an anti-tumor or anti-infection response by identifying amino acid sequences comprising δT-cells (or γT-cell) receptors chains or parts thereof that are shared between different donors. | 2021-06-17 |
20210177902 | ROR-1 SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF - Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from an anti-ROR-1 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders. | 2021-06-17 |
20210177903 | CAR T-CELLS FOR THE TREATMENT OF BONE METASTATIC CANCER - Disclosed herein is a method of providing an anti-cancer immunity in a subject with a bone metastatic cancer. The method involves co-administering to the subject an effective amount of a gamma-delta T cell stimulating agent and an effective amount of a γδ CAR T cell that binds a tumor antigen. Also disclosed herein is a recombinant T cell that expresses a gamma-delta T cell receptor (TCR) and a chimeric antigen receptor (CAR) polypeptide. | 2021-06-17 |
20210177904 | BEHAVIOURAL TREATMENT - The invention relates to the treatment and prevention of problem behaviour by the administration of a composition that includes an effective amount of | 2021-06-17 |
20210177905 | THERAPEUTIC SUBSTANCES, THEIR PREPARATION AND DIAGNOSTIC PROCEDURE - A method is described for using live mesenchymal stromal cells (MSCs) in a way which allows for identification of patients likely to respond to immunosuppressive treatment using MSCs. The method involves contacting a sample from said patient with live MSCs in vitro, and determining whether the sample is able to induce at least some apoptosis to occur in live MSCs in vitro, or detection of elevated levels of prostaglandin E2 (PGE2). The ability of the sample to induce said apoptosis and/or elevated levels of PGE2 is indicative of responsiveness of said patient to said immunosuppressive treatment and/or indicative of fitness to recover. Also provided are apoptotic MSCs for use in the treatment of immune-mediated disease or conditions, such as allo-immune or autoimmune disease, or for the prevention or treatment of rejection of a transplanted organ; or in regenerative medicine to stimulate tissue repair. Methods for preparing pharmaceutical compositions comprising the apoptotic MSCs are also described and claimed. | 2021-06-17 |
20210177906 | ADIPOSE TISSUE PARTICLE PROCESSING, TRANSFER AND STORAGE SYSTEM - An adipose tissue particle processing system includes a container and a filter screen assembly. The filter screen assembly has a first open end configured to receive adipose tissue from a syringe, and a second closed end opposite to the first open end located in the interior of the container. The filter screen assembly further includes a screen portion between the first open end and the second closed end, the screen portion including a plurality of apertures having diameters selected for processing the adipose tissue received through the first open end into controlled fat aspirate particle sizes that are output through the plurality of apertures into the interior of the container. | 2021-06-17 |
20210177907 | ENHANCED RECONSTITUTION AND AUTORECONSTITUTION OF THE HEMATOPOIETIC COMPARTMENT - The present disclosure relates to the acceleration of hematopoietic compartment reconstitution in a subject in need of hematopoietic stem cell transplantation by administering a composition having a protein transduction domain-MYC (PTD-MYC) fusion protein in combination with hematopoietic stem cell transplantation and to the enhancement of hematopoietic compartment autoreconstitution in a subject in need thereof by administering a composition having a protein transduction domain-MYC (PTD-MYC) fusion protein. | 2021-06-17 |
20210177908 | ANABOLIC TARGETING STEM CELL GENE THERAPY FOR OSTEOPOROSIS - In one aspect, anabolic agent fusion proteins and compositions comprising anabolic agent fusion proteins are provided. In some embodiments, the anabolic agent fusion protein comprises a platelet derived growth factor (PDGF) or a fibroblast growth factor (FGF) and an Asp-Ser-Ser tripeptide (DSS) repeat sequence. In another aspect, methods of promoting bone growth and methods of treating a fracture using anabolic agent fusion proteins and compositions comprising anabolic agent fusion proteins are provided. | 2021-06-17 |
20210177909 | SUPERNATANT OF BROWN ADIPOCYTES, METHOD FOR PREPARING SAME AND UTILIZATION THEREOF - The present invention provides a composition having a metabolism-improving action, which comprises a supernatant of brown adipocytes or a purified product thereof. The present invention also provides a method of preparing the supernatant without using a culture solution comprising a high concentration of glucose. The present invention also provides a method of producing brown adipocytes using pluripotent stem cells, which are useful for preparing the supernatant of brown adipocytes. The present invention has succeeded in obtaining a supernatant having a metabolism-improving action from brown adipocytes. It was also possible to obtain the supernatant without using a culture solution comprising a high concentration of glucose. The present invention has also succeeded in producing brown adipocytes from pluripotent stem cells using a feeder-free culture system without adding a cytokine cocktail or the like. The brown adipocyte supernatant of the present invention is expected to be applied to the development of therapeutic agents and cosmetic products for glucose metabolism diseases. | 2021-06-17 |
20210177910 | METHOD FOR INDUCING ANGIOGENESIS - Disclosed herewith is a method for inducing angiogenesis using modified placental tissue or an extract thereof to treat conditions other than cardiovascular conditions. | 2021-06-17 |
20210177911 | COMPOSITION AND METHOD FOR PRODUCING THE SAME - A degradation product produced by degrading a composition containing a hyaluronic acid and a protein with a protease has a pain relieving effect, a joint function ameliorating effect, a cholesterol-lowering effect, a hypoglycemic effect and a diastolic blood pressure-lowering effect. | 2021-06-17 |
20210177912 | NON-WINTERIZED, STANDARDIZED MARINE SOURCE OIL PRODUCTS AND METHODS OF MAKING THEREOF - A functional food including a supplement composition in which the supplement composition includes a non-winterized marine source oil. | 2021-06-17 |
20210177913 | USE OF HEMOLYMPH OR HEMOLYMPH COMPONENTS FOR THE TREATMENT AND PREVENTION OF INFLAMMATION AND DRY SKIN - Uses are described for hemolymph, contents of hemolymph, fragments or components of the contents found within hemolymph, including hemocyanin, any of which may be derived from crustaceans, as functional agents to treat diseases, provide symptomatic relief, provide a beautifying or relieving effect to the intended organ or site-of-intended-use, or be used as an ingredient in formulations designed to aid in the relief of pathologies or states commonly associated with inflammation and dry skin, including, but not limited to eczema, dermatitis, psoriasis, cystitis, asthma, sinusitis, joint pain, as well as other instances of acute and chronic inflammation, and for relief of general symptoms that may be associated with inflammation and dry skin but not linked directly in the intended use, including, but not limited to, redness, itchiness, irritation, muscle or joint fatigue, swelling, hydrating the skin, and reducing transepidermal water loss (TEWL). | 2021-06-17 |
20210177914 | CANNABINOID ENRICHED COMPOSITION AND METHOD OF USING - A method of treating a medical condition addressed by one or more cannabinoids, comprising providing the cannabinoid enriched solid composition to a recipient in an amount sufficient to treat the medical condition. A composition and a method to produce the composition are also disclosed. | 2021-06-17 |
20210177915 | PROBIOTICS AND METHODS OF OBTAINING SAME - This disclosure describes novel probiotics, and also describes novel methods by which such probiotics can be obtained. | 2021-06-17 |
20210177916 | LONG CHAIN DICARBOXYLIC FATTY ACID (LCDFA) PRODUCING MICROBES AND USES THEREOF - A method for increasing gastric tract acid (GTA) production in a mammalian subject. The method comprises administering a therapeutically-effective amount of a composition comprising at least one live or attenuated culture of a microbial species selected from the genus | 2021-06-17 |
20210177917 | MOLECULAR BACTERIOTHERAPY TO CONTROL SKIN ENZYMATIC ACTIVITY - The disclosure relates to composition and methods to treat dermatological diseases and disorders and to composition that modulate skin barrier permeability. | 2021-06-17 |
20210177918 | MICROBIOME BIOMARKERS IMMUNOTHERAPY RESPONSIVENESS: DIAGNOSTIC, PROGNOSTIC AND THERAPEUTIC USES THEREOF - Provided herein are compositions and methods comprising microbiome biomarkers of responsiveness/resistance to immunotherapy (e.g., anti-PD1/PD-L1 therapy), and diagnostic, prognostic and therapeutic uses thereof. In particular, the amount, identity, presence, and/or ratio of microflora in the microbiome of a subject is used to determine the responsiveness/resistance of the subject to immunotherapy, and/or the microbiome of a subject is manipulated to enhance the responsiveness of the subject to various immunotherapies and co-therapies. | 2021-06-17 |
20210177919 | IMMUNOMODULATORY COMPOSITION COMPRISING LACTOBACILLUS-DERIVED EXTRACELLULAR VESICLES - The present specification discloses an immunomodulatory composition comprising | 2021-06-17 |